Search results
AbbVie's ovarian cancer therapy succeeds in mid-stage trial
Reuters· 3 hours agoThe U.S. Food and Drug Administration had in March approved the treatment for use in patients with...
AbbVie treats first subject in Phase III multiple myeloma drug trial
Clinical Trials Arena via Yahoo Finance· 8 hours agoAbbVie has treated the first subject in the Phase III CERVINO clinical trial of its investigational...
2 High-Yield Dividend Stocks to Buy Right Now | The Motley Fool
The Motley Fool· 1 day agoDividend stocks are sensitive to interest rates. When rates fall, studies show that money managers...
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
Zacks via Yahoo Finance· 3 days agoAbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing...
AbbVie’s RINVOQ now indicated for paediatric arthritis in US
Pharmaceutical Technology via Yahoo Finance· 1 day agoAbbVie has announced that its RINVOQ (upadacitinib) is now indicated for treating polyarticular...
ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
FierceBiotech· 2 days agoA new trend has emerged at this year’s American Society of Clinical Oncology conference: the...
AbbVie (ABBV) Could Be a Great Choice
Zacks via Yahoo Finance· 3 days agoDividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?...
AbbVie (ABBV) Soars 3.2%: Is Further Upside Left in the Stock?
Zacks via Yahoo Finance· 3 days agoAbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than...
AbbVie Inc. (NYSE:ABBV) Receives $176.14 Average PT from Brokerages
ETF DAILY NEWS· 3 days agoShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have earned an average rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, ...
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
Zacks via Yahoo Finance· 3 days agoThe latest trading session saw AbbVie (ABBV) ending at $160.19, denoting a -0.65% adjustment from...